12 of 12

Application No. Amendment Dated Reply to Office Action of 10/536,729 05/18/2006 04/13/2006

Remarks/Arguments

Claims 19-23 are as originally presented. Claims 11-13, 15, and 18 were previously amended. Claims 1, and 5-9 are currently amended. Claims 2-4, 10, 14, 16, and 17 are cancelled. The amended claims are supported by the specification and do not present any new matter.

Applicants are required to make an election in light of the Examiner's Action mailed April13, 2006. Applicants discussed the restriction requirement with the Examiner on May 15, 2006 and proposed an alternative group for election. In light of that discussion, Applicants amended claim 1 and subsequent claims as provided herein. Applicants communicated the proposed changes with the Examiner by facsimile transmittal. The Examiner indicated that he was amenable to the Applicants' proposed alternative group for election.

Applicants further identily the compound of Example 2 (see page 59 of the Specification) as a species within the scope of amended claim 1. The chemical structure of Example 3 is provided here for the Examiner's convenience.

Example 3

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100859-1P US.

Respectfully submitted,

Nàme:

Heidi Berven

Dated:

05/18/2006

Reg. No.:

48,951

Phone No.:

781-839-4336

Global Intellectual Property, Patents,

AstraZeneca R&D Boston,

35, Gatehouse Drive.

Waltham,

MA 02451